These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 10524884

  • 1. A randomized double-blind study assessing 4 versus 8 mg. doxazosin for benign prostatic hyperplasia.
    MacDiarmid SA, Emery RT, Ferguson SF, McGuirt-Franklin R, McIntyre WJ, Johnson DE.
    J Urol; 1999 Nov; 162(5):1629-32. PubMed ID: 10524884
    [Abstract] [Full Text] [Related]

  • 2. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P, Kirby RS.
    Fortschr Med Orig; 2000 Jul 27; 118 Suppl 2():83-92. PubMed ID: 15700491
    [Abstract] [Full Text] [Related]

  • 3. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
    de Reijke TM, Klarskov P.
    BJU Int; 2004 Apr 27; 93(6):757-62. PubMed ID: 15049986
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction.
    Kirby RS, O'Leary MP, Carson C.
    BJU Int; 2005 Jan 27; 95(1):103-9; discussion 109. PubMed ID: 15638905
    [Abstract] [Full Text] [Related]

  • 5. Apoptotic regression of prostatic tissue induced by short-term doxazosin treatment in benign prostatic hyperplasia.
    Türkeri LN, Ozyürek M, Ersev D, Akdaş A.
    Arch Esp Urol; 2001 Mar 27; 54(2):191-6. PubMed ID: 11341128
    [Abstract] [Full Text] [Related]

  • 6. A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia.
    Roehrborn CG, Prajsner A, Kirby R, Andersen M, Quinn S, Mallen S.
    Eur Urol; 2005 Sep 27; 48(3):445-52; discussion 452. PubMed ID: 15996811
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin].
    Suzuki H, Ohnishi T, Ikemoto I, Ohishi Y, Suzuki Y, Yamazaki H.
    Hinyokika Kiyo; 2001 Feb 27; 47(2):77-81. PubMed ID: 11280890
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Doxazosin treatment of disorders of the voiding phase in benign prostatic hyperplasia].
    Esteban Fuertes M, Salinas Casado J, Virseda Chamorro M, Ramírez Fernández JC, Salomon Moh'd S, Luengo Alpuente S, Resel Estévez L.
    Arch Esp Urol; 1997 Dec 27; 50(10):1057-66. PubMed ID: 9494194
    [Abstract] [Full Text] [Related]

  • 15. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia.
    Schulman CC, Lock TM, Buzelin JM, Boeminghaus F, Stephenson TP, Talja M, European Tamsulosin Study Group.
    J Urol; 2001 Oct 27; 166(4):1358-63. PubMed ID: 11547074
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Morning versus evening dosing with doxazosin in benign prostatic hyperplasia: pharmacokinetics, efficacy and safety.
    Kirby RS.
    Int J Clin Pract; 1998 Mar 27; 52(2):75-7. PubMed ID: 9624784
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.